ReviewCancers2024
Cutaneous Squamous Cell Carcinoma in Patients with Solid-Organ-Transplant-Associated Immunosuppression.
Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Tongue Carcinoma in Immunosuppressed Patients After Liver and Kidney Transplantation: A Case Series.Annals of transplantation · 2026Article
- Neoadjuvant intent anti-programmed death-1 immunotherapy for cutaneous squamous cell carcinoma in patients with hematologic malignancy.The oncologist · 2026Article
- Non-Melanoma Skin Cancer in Transplant Recipients: A Single-Centre Retrospective Cohort Study on the Role of Transplant Type, Immunosuppressive Exposure, and Tumor Subtypes.Clinical transplantation · 2026Article
- Belatacept in Solid Organ Transplantation: Current Kidney Applications, Future Perspectives in Other Organs, and Clinical Implications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Tumor Infiltrating Lymphocytes in Cutaneous Squamous Cell Carcinoma-A Systematic Review.Dermatopathology (Basel, Switzerland) · 2026Review
- Novel Immunotherapeutic Approaches for Patients with Head and Neck Cutaneous Squamous Cell Carcinoma.Oncology research · 2026Review
- Advanced Cutaneous Squamous Cell Carcinoma: Biology, Immunotherapy, and Evolving Prognostic Factors.Biomedicines · 2025Review
- Environmental greenery and skin cancer risk: a prospective cohort study on incidence and mediating mechanisms.Archives of public health = Archives belges de sante publique · 2025Article
- Review
- The burden of skin cancer in heart transplant recipients: Impact of immunosuppressive regimens.JHLT open · 2025Article
- Squamous Cell Carcinoma of the Nail Unit: A Comprehensive Review of Clinical Features, Diagnostic Workflow, Management Strategies and Therapeutic Options.Diagnostics (Basel, Switzerland) · 2025Review
- A Comprehensive Narrative Review of the Challenges Surrounding Cutaneous SCC.Dermatology and therapy · 2025Review
- Article
- Predicting Behavior of Cutaneous Head and Neck Squamous Cell Carcinoma in Transplant Recipients.OTO openArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The management of advanced cutaneous squamous cell carcinoma (CSCC) has been revolutionized by the introduction of immunotherapy. Yet, successful treatment with immunotherapy relies on an adequate antitumor immune response. Patients who are solid-organ transplant recipients (SOTRs) have a higher incidence of CSCC compared to the general population. This review discusses the current knowledge of epidemiology, pathophysiology, and management of patients with CSCC who are immunocompromised because of their chronic exposure to immunosuppressive medications to prevent allograft rejection. First, we discuss the prognostic impact of immunosuppression in patients with CSCC. Next, we review the risk of CSCC development in immunosuppressed patients due to SOT. In addition, we provide an overview of the biological immune disruption present in transplanted immunosuppressed CSCC patients. We discuss the available evidence on the use of immunotherapy and provide a framework for the management approach with SOTRs with CSCC. Finally, we discuss potential novel approaches that are being investigated for the management of immunosuppressed patients with CSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.